03320 CHINARES PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 1.41X | Oper Margin | 5.0% |
|---|---|---|---|
| LT Debt/Equity | 49.0% | Net Margin | 1.3% |
| Total Debt/Equity | 143.0% | Return on Equity | 6.9% |
| Price/Book | 0.67X | Return on Assets | 1.3% |
| (HKD 5.510) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 3,542.81 | 4,248.15 | 3,924.50 | 3,768.89 | 3,297.13 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | -16.6 | +8.3 | +4.1 | +14.3 | +0.3 |
| Earnings Per Share (HKD) | 0.564 | 0.676 | 0.625 | 0.6 | 0.525 |
| Earnings Per Share Growth (%) | -16.6 | +8.2 | +16.8 | +14.3 | +0.4 |
| Dividend Per Share (HKD) | 0.146 | 0.170 | 0.160 | 0.150 | 0.120 |
| P/E* (X) | 9.77 | 8.15 | 8.82 | 9.18 | 10.50 |
| Yield (%) | 2.65 | 3.08 | 2.90 | 2.72 | 2.18 |
| Dividend Share (%) | 25.91 | 25.10 | 25.61 | 25.00 | 22.87 |
| Book NAV (HKD) | 8.167 | 8.063 | 7.773 | 8.115 | 7.396 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 257,673 | 244,704 | +5.3 | 218,183 |
| Operating Result | 10,492 | 9,399 | +11.6 | 7,694 |
| Associates | 368.014 | 417.106 | -11.8 | 332.341 |
| Profit Before Taxation | 10,930 | 9,880 | +10.6 | 8,361 |
| Taxation | 2,527 | 2,105 | +20.0 | 1,703 |
| Profit /( Loss) After Taxation | 8,403 | 7,775 | +8.1 | 6,658 |
| Minority Interests | 5,052 | 3,921 | +28.8 | 3,158 |
| Net Profit | 3,331 | 3,854 | -13.6 | 3,500 |
| Earnings Per Share () | 0.5639 | 0.6762 | -16.6 | 0.6247 |
| Dividend Per Share () | 0.1461 | 0.1697 | -13.9 | 0.1600 |
| Announcement Date | 2025-03-26 | 2024-03-26 | NA | 2023-03-30 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
